IP Library Granted Patent US 8,623,892
Granted Patent B2
US 8,623,892 · App. 13/784,466 · Granted Jan 7, 2014

Metalloenzyme inhibitor compounds

Inventors: William J. Hoekstra (Durham, NC); Robert J. Schotzinger (Raleigh, NC); Stephen W. Rafferty (Durham, NC)
Assignee: Viamet Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,623,892
App. No.
13/784,466
Granted
Jan 7, 2014
Kind
B2
Abstract

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Claims (13)

1. A method of treating a subject suffering from or susceptible to a metalloenzyme-related disorder or disease, comprising administering to the subject an effective amount of a compound of formula (III) or salt thereof:

wherein X is CH, Y is CH, R 2 is alkyl, R 3 is OH, and R 4 and R 5 are independently H, halogen, alkoxy, fluoroalkoxy containing 1-5 fluorines, cyano, carboxamido, optionally substituted aryl, or optionally substituted heteroaryl.

2. The method of claim 1 , wherein the disease or disorder is cancer.

3. The method of claim 1 , wherein the disease or disorder is prostate cancer.

4. The method of claim 1 , wherein the compound of formula (III) is:

1-(6,7-Dimethoxynaphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol (1);

1-(6,7-Bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol (3);

2-Methyl-1-(6-(oxazol-5-yl)naphthalen-2-yl)- 1 -(1H-1,2,3-triazol-4-yl)propan-1-ol (4);

2-methyl-1-(1H-1,2,3-triazol-4-yl)-1-(6-(2,2,2-trifluoroethoxy)naphthalen-2-yl)propan-1-ol (12);

1-(6-(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol (13);

or salt thereof.

5. The method of claim 4 , wherein the disease or disorder is cancer.

6. The method of claim 4 , wherein the disease or disorder is prostate cancer.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: INNOCRIN PHARMACEUTICALS HOLDINGS, LLC
To: KEMBI THERAPEUTICS PTY LTD
Reel/Frame 055635/0883 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2021
From: INNOCRIN PHARMACEUTICALS, INC.
To: INNOCRIN PHARMACEUTICALS HOLDINGS, LLC
Reel/Frame 055518/0691 →
CHANGE OF NAME Recorded Oct 27, 2014
From: VIAMET PHARMACEUTICALS, INC.
To: INNOCRIN PHARMACEUTICALS, INC.
Reel/Frame 034066/0290 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2013
From: HOEKSTRA, WILLIAM J.; SCHOTZINGER, ROBERT J.; RAFFERTY, STEPHEN W.
To: VIAMET PHARMACEUTICALS, INC.
Reel/Frame 030382/0480 →
Continuity (3)
Division 13293891 · Nov 10, 2011
Provisional Application 61413395 · Nov 13, 2010
Related Publication 20130184309A1 · Jul 18, 2013